# COL1A2

## Overview
The COL1A2 gene encodes the collagen type I alpha 2 chain, a crucial component of type I collagen, which is the most abundant collagen type in the human body. This gene plays a significant role in the formation of the extracellular matrix, contributing to the structural integrity and tensile strength of connective tissues such as skin, bone, tendons, and ligaments. The protein product of COL1A2, categorized as a structural protein, combines with two alpha-1 chains to form a stable triple helix, essential for the proper assembly and function of collagen fibers (Maruelli2020Osteoblasts). The expression and regulation of COL1A2 are influenced by various signaling pathways, including Transforming Growth Factor-beta (TGF-β), which underscores its importance in tissue formation and repair (Inagaki1994Transforming). Mutations in COL1A2 are linked to several connective tissue disorders, such as osteogenesis imperfecta and Ehlers-Danlos syndrome, highlighting its clinical significance (Pollitt2006Mutation; Hatamochi2014The).

## Structure
The COL1A2 gene encodes the alpha-2 chain of type I collagen, a major structural protein in the bone matrix. The primary structure of this protein consists of a repeating Gly-X-Y sequence, where glycine is invariantly present at every third position, and X and Y are often proline and hydroxyproline (Pollitt2006Mutation). This sequence forms a triple helical domain composed of 1014 amino acids, which is crucial for the stability and function of the collagen molecule (Pollitt2006Mutation).

The secondary structure of the alpha-2 chain involves the formation of a stable triple helix, which is a characteristic feature of fibrillar collagens. This triple helix is flanked by globular carboxyl and amino terminal peptides (Pollitt2006Mutation). The tertiary and quaternary structures involve the assembly of three collagen chains into a stable triple helix, which is essential for the proper function and secretion of collagen (Willing1988Heterozygosity).

Post-translational modifications, such as hydroxylation and glycosylation, are important for the stability and secretion of the collagen triple helix. These modifications occur in the rough endoplasmic reticulum and are crucial for proper collagen assembly and function (Willing1988Heterozygosity). Disruptions in these processes can lead to conditions such as osteogenesis imperfecta (Willing1988Heterozygosity).

## Function
The COL1A2 gene encodes the alpha-2 chain of type I collagen, a critical component of the extracellular matrix in various tissues, including skin, bone, tendons, and ligaments. In healthy human cells, COL1A2 contributes to the formation of a triple helix structure by combining with two alpha-1 chains, which is essential for the tensile strength and structural integrity of connective tissues (Maruelli2020Osteoblasts). This structural protein is synthesized primarily in fibroblasts and osteoblasts, where it plays a vital role in tissue formation and repair (Maruelli2020Osteoblasts).

Type I collagen, which includes the COL1A2-encoded alpha-2 chain, is crucial for maintaining the structural integrity of the bone matrix. It is synthesized as a soluble precursor, procollagen I, which undergoes post-translational modifications to form mature collagen fibers (Pollitt2006Mutation). The proper assembly and function of type I collagen are essential for normal bone development and maintenance, as disruptions can lead to disorders such as osteogenesis imperfecta (Wenstrup1993Mutations). The COL1A2 protein is active in the extracellular space, where it interacts with other matrix components to support cellular and tissue functions (Wang2023COL1A2).

## Clinical Significance
Mutations in the COL1A2 gene are associated with several genetic disorders, primarily affecting connective tissues. Osteogenesis imperfecta (OI), commonly known as brittle bone disease, is one of the most prevalent conditions linked to COL1A2 mutations. This disorder is characterized by increased bone fragility and susceptibility to fractures. Mutations in COL1A2, particularly those involving glycine substitutions in the triple helix region of type I collagen, can lead to various types of OI, ranging from mild to severe phenotypes (Lu2019Molecular; Pollitt2006Mutation).

Ehlers-Danlos syndrome (EDS), specifically the arthrochalasia type, is another condition associated with COL1A2 mutations. This type of EDS is marked by joint hypermobility, skin hyperextensibility, and tissue fragility. Mutations in the COL1A2 gene, such as those affecting the exon 6 donor splice site, can lead to defective collagen fibril organization, contributing to the clinical manifestations of EDS (Lu2019Molecular; Hatamochi2014The).

Additionally, COL1A2 mutations have been implicated in dentinogenesis imperfecta (DI), a condition affecting tooth structure. These mutations can result in dysplastic dentin and irregular dentinal tubules, leading to increased tooth fragility and risk of fracture (Intarak2020Tooth).

## Interactions
The COL1A2 gene encodes the alpha-2 chain of type I collagen, which is a major component of the extracellular matrix and plays a crucial role in tissue structure and function. COL1A2 interacts with other collagen chains, such as COL1A1, to form a stable triple helix structure, which is essential for the integrity of connective tissues. This interaction is fundamental to the formation of collagen fibers, which provide tensile strength to tissues.

In addition to its structural role, COL1A2 is involved in various cellular interactions. It has been shown to interact with fibronectin and integrins, which are proteins involved in cell adhesion and signaling. These interactions are important for cell-matrix communication and can influence cell behavior, including migration and proliferation.

The regulation of COL1A2 expression is influenced by several signaling pathways. Transforming Growth Factor-beta (TGF-β) stimulates COL1A2 expression through a cis-acting element in its promoter that contains an Sp1-binding site. This interaction is crucial for the transcriptional activation of COL1A2 in response to TGF-β, highlighting the role of Sp1 as a key transcription factor in this process (Inagaki1994Transforming). Additionally, the phosphorylation of transcription factors that bind to the COL1A2 promoter is necessary for its activity, indicating the involvement of signal transduction pathways in regulating its expression (Leaner2006Phosphorylation).


## References


[1. (Hatamochi2014The) Atsushi Hatamochi, Takahiro Hamada, Makoto Yoshino, and Takashi Hashimoto. The first japanese case of the arthrochalasia type of ehlers–danlos syndrome with col1a2 gene mutation. Gene, 538(1):199–203, March 2014. URL: http://dx.doi.org/10.1016/j.gene.2014.01.033, doi:10.1016/j.gene.2014.01.033. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2014.01.033)

[2. (Lu2019Molecular) Yanqin Lu, Shie Zhang, Yanzhou Wang, Xiuzhi Ren, and Jinxiang Han. Molecular mechanisms and clinical manifestations of rare genetic disorders associated with type i collagen. Intractable &amp; Rare Diseases Research, 8(2):98–107, May 2019. URL: http://dx.doi.org/10.5582/irdr.2019.01064, doi:10.5582/irdr.2019.01064. This article has 27 citations.](https://doi.org/10.5582/irdr.2019.01064)

[3. (Wang2023COL1A2) Yi Wang, Maki Sakaguchi, Hemragul Sabit, Sho Tamai, Toshiya Ichinose, Shingo Tanaka, Masashi Kinoshita, Yasuo Uchida, Sumio Ohtsuki, and Mitsutoshi Nakada. Col1a2 inhibition suppresses glioblastoma cell proliferation and invasion. Journal of Neurosurgery, 138(3):639–648, March 2023. URL: http://dx.doi.org/10.3171/2022.6.jns22319, doi:10.3171/2022.6.jns22319. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.3171/2022.6.jns22319)

[4. (Wenstrup1993Mutations) Richard J. Wenstrup, Laura W. Lever, Charlotte L. Phillips, and L. Darryl Quarles. Mutations in the col1a2 gene of type i collagen that result in nonlethal forms of osteogenesis imperfecta. American Journal of Medical Genetics, 45(2):228–232, January 1993. URL: http://dx.doi.org/10.1002/ajmg.1320450215, doi:10.1002/ajmg.1320450215. This article has 6 citations.](https://doi.org/10.1002/ajmg.1320450215)

[5. (Inagaki1994Transforming) Y. Inagaki, S. Truter, and F. Ramirez. Transforming growth factor-beta stimulates alpha 2(i) collagen gene expression through a cis-acting element that contains an sp1-binding site. Journal of Biological Chemistry, 269(20):14828–14834, May 1994. URL: http://dx.doi.org/10.1016/s0021-9258(17)36699-1, doi:10.1016/s0021-9258(17)36699-1. This article has 256 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(17)36699-1)

[6. (Maruelli2020Osteoblasts) Silvia Maruelli, Roberta Besio, Julie Rousseau, Nadia Garibaldi, Jérôme Amiaud, Bénédicte Brulin, Pierre Layrolle, Virginie Escriou, Antonio Rossi, Valerie Trichet, and Antonella Forlino. Osteoblasts mineralization and collagen matrix are conserved upon specific col1a2 silencing. Matrix Biology Plus, 6–7:100028, May 2020. URL: http://dx.doi.org/10.1016/j.mbplus.2020.100028, doi:10.1016/j.mbplus.2020.100028. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mbplus.2020.100028)

[7. (Willing1988Heterozygosity) M C Willing, D H Cohn, B Starman, K A Holbrook, C R Greenberg, and P H Byers. Heterozygosity for a large deletion in the alpha 2(i) collagen gene has a dramatic effect on type i collagen secretion and produces perinatal lethal osteogenesis imperfecta. Journal of Biological Chemistry, 263(17):8398–8404, June 1988. URL: http://dx.doi.org/10.1016/s0021-9258(18)68491-1, doi:10.1016/s0021-9258(18)68491-1. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)68491-1)

[8. (Pollitt2006Mutation) Rebecca Pollitt, Robert McMahon, Janice Nunn, Robert Bamford, Amal Afifi, Nicholas Bishop, and Ann Dalton. Mutation analysis ofcol1a1andcol1a2in patients diagnosed with osteogenesis imperfecta type i-iv. Human Mutation, 27(7):716–716, July 2006. URL: http://dx.doi.org/10.1002/humu.9430, doi:10.1002/humu.9430. This article has 87 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.9430)

[9. (Leaner2006Phosphorylation) Virna Leaner and M. Parker. Phosphorylation of the α 2(1) procollagen promoter binding proteins is required for promoter activity. IUBMB Life (International Union of Biochemistry and Molecular Biology: Life), 58(2):97–102, February 2006. URL: http://dx.doi.org/10.1080/15216540600644820, doi:10.1080/15216540600644820. This article has 1 citations.](https://doi.org/10.1080/15216540600644820)

[10. (Intarak2020Tooth) Narin Intarak, Thunyaporn Budsamongkol, Thanakorn Theerapanon, Theerapat Chanamuangkon, Anucharte Srijunbarl, Lawan Boonprakong, Thantrira Porntaveetus, and Vorasuk Shotelersuk. Tooth ultrastructure of a novel col1a2 mutation expanding its genotypic and phenotypic spectra. Oral Diseases, 27(5):1257–1267, October 2020. URL: http://dx.doi.org/10.1111/odi.13657, doi:10.1111/odi.13657. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/odi.13657)